Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com

StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a report released on Thursday. The brokerage issued a sell rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Price Performance

Shares of NASDAQ:CYCC opened at $0.37 on Thursday. The firm has a fifty day moving average price of $0.36 and a two-hundred day moving average price of $0.65. Cyclacel Pharmaceuticals has a one year low of $0.30 and a one year high of $4.00. The company has a market cap of $2.32 million, a price-to-earnings ratio of -0.04 and a beta of 0.35.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.